Dashboard
The company has declared Negative results for the last 8 consecutive quarters
- OPERATING CASH FLOW(Y) Lowest at USD -116.05 MM
- ROCE(HY) Lowest at -363.16%
- DEBTORS TURNOVER RATIO(HY) Lowest at 2.92 times
Risky - Negative EBITDA
Rising Promoter Confidence
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 2,409 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-1.55
-978.90%
158.59
Total Returns (Price + Dividend) 
Liquidia Corp. for the last several years.
Risk Adjusted Returns v/s 
News
Is Liquidia Corp. technically bullish or bearish?
As of 5 August 2025, the technical trend for Liquidia Corp. has changed from mildly bullish to bullish. The MACD is bullish on both weekly and monthly timeframes, and moving averages indicate a bullish stance on the daily timeframe. However, the Dow Theory shows a mixed signal with a mildly bearish weekly outlook and a mildly bullish monthly outlook. The Bollinger Bands are mildly bullish on both weekly and monthly timeframes, while the KST is bullish on both timeframes. The OBV presents a mildly bearish weekly signal but is bullish monthly. Liquidia Corp. has demonstrated strong performance compared to the S&P 500, with a year-to-date return of 109.78% versus the S&P 500's 12.22%, and a one-year return of 148.94% compared to 17.14%. Overall, the current technical stance is bullish, supported by strong MACD and moving average indicators, despite some mixed signals from Dow Theory and OBV....
Read MoreIs Liquidia Corp. overvalued or undervalued?
As of 13 May 2021, the valuation grade for Liquidia Corp. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 31.19 and negative EV to EBIT and EV to EBITDA ratios of -11.61 and -11.80, respectively. Additionally, its Return on Equity (ROE) is alarmingly low at -271.66%, further suggesting that the company is struggling to generate returns for shareholders. In comparison to its peers, Liquidia Corp.'s P/E ratio of -16.20 is less favorable than Harrow, Inc. at -147.53 and Zymeworks, Inc. at -15.61, both of which also exhibit risky valuations. Notably, while Liquidia has shown impressive returns over longer periods, such as 311.85% over three years compared to the S&P 500's 70.41%, its recent performance has been disappointing, with a 1-week return of -8.63 versus the S&P 500's 1.05%...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 38 Schemes (13.53%)
Held by 57 Foreign Institutions (3.93%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 183.87% vs 6.90% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is -8.33% vs 0.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -20.00% vs 10.06% in Dec 2023
YoY Growth in year ended Dec 2024 is -66.11% vs -91.46% in Dec 2023






